Edesa Biotech, Inc.

NasdaqCM EDSA

Edesa Biotech, Inc. Free Cash Flow for the year ending September 30, 2024: USD -4.89 M

Edesa Biotech, Inc. Free Cash Flow is USD -4.89 M for the year ending September 30, 2024, a 26.31% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Edesa Biotech, Inc. Free Cash Flow for the year ending September 30, 2023 was USD -6.64 M, a 45.98% change year over year.
Edesa Biotech, Inc. Free Cash Flow for the year ending September 30, 2022 was USD -12.28 M, a 10.14% change year over year.
Edesa Biotech, Inc. Free Cash Flow for the year ending September 30, 2021 was USD -13.67 M, a -172.30% change year over year.
Edesa Biotech, Inc. Free Cash Flow for the year ending September 30, 2020 was USD -5.02 M, a -3.44% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: EDSA

Edesa Biotech, Inc.

CEO	Dr. Pardeep Nijhawan FRCPC, M.D.
IPO Date	June 21, 2010
Location	Canada
Headquarters	100 Spy Court
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Key trends

Past 5 years